Immune Thrombocytopenia — Research Summary
Printed from RareWays (rareways.com.au) on 5 April 2026
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
Single-cell transcriptome deciphers key targets of thrombopoietin receptor agonists and immune microenvironment characteristics of immune thrombocytopenia.
Wang Wanru et al. — Platelets (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41918402/
- 2.
Abnormal expansion of peripheral helper T cells in primary immune thrombocytopenia.
Liu Qian et al. — Platelets (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41914348/
- 3.
Hematologic adverse events following COVID-19 vaccination and revaccination in persons aged 12 and above: A Canadian Immunization Research Network study.
Smolinski Michael et al. — Human vaccines & immunotherapeutics (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41848549/
- 4.
Efficacy and safety of TPO-RA combined with sirolimus in the treatment of relapsed immune thrombocytopenia.
Wang Dan et al. — Hematology (Amsterdam, Netherlands) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41844533/
- 5.
Propofol and/or etomidate-induced immune thrombocytopenia: A case report.
Wang Kai et al. — Hematology (Amsterdam, Netherlands) (1 December 2026)
https://pubmed.ncbi.nlm.nih.gov/41762035/
Clinical Trials — Currently Recruiting (Australia)
Ask your doctor whether you or your child may be eligible for any of these trials.
- 1.
Efficacy and Safety of Nemtabrutinib (MK-1026) in Participants With Hematologic Malignancies (MK-1026-003)
Recruiting — Phase 2 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT04728893
- 2.
A Study of Nemtabrutinib Plus Venetoclax vs Venetoclax + Rituximab (VR) in Second-line (2L) + Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) (MK-1026-010/BELLWAVE-010).
Recruiting — Phase 3 — Merck Sharp & Dohme LLC
https://clinicaltrials.gov/study/NCT05947851
- 3.
Study of Ultomiris® (Ravulizumab) Safety in Pregnancy
Recruiting — Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT06312644
- 4.
A Study of Transcatheter Aortic Valve Replacement Case Selection and Valve Sizing Using the ABC Bicuspid Sizing Algorithm
Recruiting — World Health Research Inc.
https://clinicaltrials.gov/study/NCT06991517
- 5.
Creating A Risk Assessment Tool for Thunderstorm Asthma: the CARISTA Study
Recruiting — Na — University of Melbourne
https://clinicaltrials.gov/study/NCT07055542
- 6.
C-Brace Prospective Registry
Recruiting — Otto Bock Healthcare Products GmbH
https://clinicaltrials.gov/study/NCT04640584
- 7.
Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell Disorders
Recruiting — Phase 2 — Incyte Corporation
https://clinicaltrials.gov/study/NCT07104565
- 8.
Benefits of Choir for Older Adults With Unaddressed Hearing Loss (WP2)
Recruiting — Na — Toronto Metropolitan University
https://clinicaltrials.gov/study/NCT06580847
- 9.
Antidepressant Effects of Nitrous Oxide
Recruiting — Phase 2 — University of Chicago
https://clinicaltrials.gov/study/NCT05357040
- 10.
Phase 1b Trial of RAY121 in Immunological Diseases (RAINBOW Trial)
Recruiting — Phase 1 — Chugai Pharmaceutical
https://clinicaltrials.gov/study/NCT06371417
- 11.
OM336 in Autoimmune Cytopenias
Recruiting — Phase 1 — Ouro Medicines
https://clinicaltrials.gov/study/NCT07083960
- 12.
Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford
Recruiting — Sanford Health
https://clinicaltrials.gov/study/NCT01793168
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Immune Thrombocytopenia
Immune Thrombocytopenia is an autoimmune disorder in which the immune system destroys platelets, causing low platelet counts and bleeding complications. It can occur at any age and may be acute (common in children) or chronic (more common in adults). Treatment ranges from watchful waiting to corticosteroids, intravenous immunoglobulin, and thrombopoietin receptor agonists.
Most Recent Research
Thrombopoietin receptor agonists (TPO-RAs) represent a cornerstone in immune thrombocytopenia (ITP) management, yet their molecular mechanisms remain incompletely elucidated. This study systematically deciphered the key targets and signaling networks of four TPO-RAs (romiplostim, eltrombopag, avatrombopag, hetrombopag) in ITP pathogenesis. Network pharmacology was integrated with single-cell high-dimensional weighted gene co-expression network analysis (hdWGCNA) using bone marrow scRNA-seq data from ITP patients and healthy controls. Metacell-based co-expression modules to hematopoietic bone marrow cells were identified. Drug targets were curated from multiple databases, and candidate genes were screened by intersecting differentially expressed genes (DEGs), cell specific modules, and TPO-RA targets. Molecular docking, pseudotime trajectory analysis, and in silico gene knockdown were employed for functional validation. Intersection analysis revealed five key genes (CACNA1A, CSF1R, PKN1, CD9, DSTYK). Molecular docking demonstrated strong binding affinities between TPO-RAs and key targets. The ITP bone marrow niche exhibited rewired cell-cell communication, with enhanced T cell-initiated signaling and aberrant megakaryocyte-T cell interactions. Pseudotime analysis uncovered disrupted megakaryocyte maturation dynamics. In silico knockdown revealed CACNA1A, CSF1R, and PKN1 dysregulation exacerbated neutrophil hyperactivity, while CD9 and DSTYK knockdown impaired mitotic regulation. This study delineated mechanisms of TPO-RAs, highlighting five key genes that orchestrate dysregulated thrombopoiesis and immune dysfunction in ITP. The integration of in silico strategies identified novel targets for optimizing ITP therapy.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.